NCT06291155View on ClinicalTrials.gov

Mechanism of SGLT2 Inhibition in the Kidney

PHASE4RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2028

Conditions
Type 2 DiabetesDiabetic Kidney Disease
Interventions
DRUG

SGLT2 inhibitor

All participants will be receive 100 mg/daily doses of Canagliflozin (INVOKANA) for 6 months. Canagliflozin is a Sodium-glucose cotransporter 2 (SGLT2) inhibitor

Trial Locations (1)

48109

RECRUITING

University of Michigan, Ann Arbor

All Listed Sponsors
collaborator

University of Colorado, Denver

OTHER

collaborator

Renal Pre-Competitive Consortium (RPC3)

UNKNOWN

lead

University of Michigan

OTHER